Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies

1

Monoclonal antibodies targeting Plasmodium falciparum CSP are candidates for malaria prevention in vulnerable populations.
2

The TCR assay indicated varying degrees of cross-reactivity for mAbs 317 and 311, while CIS43 showed no TCR positivity.
3

Fc modifications improved the binding affinity of mAb 311 to the human neonatal Fc receptor, enhancing its pharmacokinetic profile.
4

MAb 311-LS demonstrated safety and improved pharmacokinetics compared to the wild-type mAb 311 in rhesus models.
5

Evaluating TCR liabilities early in mAb development is critical for optimizing safety and efficacy in clinical applications.

Frontiers In Immunology

by William R. Fugina, Dallas R. Brown, Shelby Foor, Emma C. Ryan, Samuel Cuevas, Shreeram Nallar, Dawn Wolf, Renita Brown, Jesse P. Deluca, Geoffrey C. Chin, Elizabeth J. Raymond, James T. Raymond, Phil S. Medlin, Sheetij Dutta
June 23, 2026

1